SECTOR
Aurobindo Pharma’s arm obtains marketing authorization for Dazublys
Jul-03-2025

Aurobindo Pharma’s wholly owned step-down subsidiary -- CuraTeQ Biologics s.r.o. has obtained marketing authorization from the European Commission for Dazublys, its trastuzumab biosimilar version.

Earlier in April 2025, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Dazublys, recommending its marketing authorization. This is CuraTeQ’s third biosimilar to be approved by EMA after the approval of Dyrupeg in April 2025 and Zefylti in February 2025, and the fourth overall in the EU, alongside the approval of Bevqolva by the UK’s MHRA in December 2024.

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.

  RELATED NEWS >>